Last reviewed · How we verify
Olbemox (ACIPIMOX)
Olbemox (generic name: ACIPIMOX) is a acipimox drug. It is currently in Phase 3 development for Hyperlipoproteinemia.
Olbemox works by activating the hydroxycarboxylic acid receptor 2, which helps to reduce the production of triglycerides in the liver.
Olbemox is a small molecule with an unknown mechanism of action. It has been studied in clinical trials for conditions such as hypopituitarism, insulin resistance, and metabolic diseases, and has been compared to acipimox and placebo in these studies.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ACIPIMOX |
|---|---|
| Drug class | acipimox |
| Target | Hydroxycarboxylic acid receptor 2 |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Think of it like a key that unlocks a process in the liver. When activated, the hydroxycarboxylic acid receptor 2 helps to slow down the production of triglycerides, which are a type of fat that can build up in the blood and increase the risk of heart disease. This can help to lower cholesterol levels and improve overall heart health.
Approved indications
- Hyperlipoproteinemia
Common side effects
Key clinical trials
- Ketones, SGLT2, HFrEF (EARLY_PHASE1)
- Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia (PHASE2)
- Forearm Immobilization, Metabolic Health, and Muscle Loss (NA)
- Glucose and Glycogen Dynamics in Prediabetes
- Can Brisk Walking Combined With Ingestion of a Lipid-lowering Drug Improve Fat Metabolism in Muscle? (NA)
- Can the Health Benefits of a Walking-based Exercise Programme be Enhanced by Co-ingestion of a Lipid-lowering Drug? (NA)
- The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome (PHASE2,PHASE3)
- Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olbemox CI brief — competitive landscape report
- Olbemox updates RSS · CI watch RSS
Frequently asked questions about Olbemox
What is Olbemox?
How does Olbemox work?
What is Olbemox used for?
What is the generic name of Olbemox?
What drug class is Olbemox in?
What development phase is Olbemox in?
What does Olbemox target?
Related
- Drug class: All acipimox drugs
- Target: All drugs targeting Hydroxycarboxylic acid receptor 2
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Hyperlipoproteinemia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing